MX2024001242A - Una composicion farmaceutica para la obtencion de imagenes. - Google Patents
Una composicion farmaceutica para la obtencion de imagenes.Info
- Publication number
- MX2024001242A MX2024001242A MX2024001242A MX2024001242A MX2024001242A MX 2024001242 A MX2024001242 A MX 2024001242A MX 2024001242 A MX2024001242 A MX 2024001242A MX 2024001242 A MX2024001242 A MX 2024001242A MX 2024001242 A MX2024001242 A MX 2024001242A
- Authority
- MX
- Mexico
- Prior art keywords
- pudexacianinium
- intraoperative
- ureter
- nirf
- nirf imaging
- Prior art date
Links
- 101100483734 Mus musculus Uhrf2 gene Proteins 0.000 title 1
- 238000003384 imaging method Methods 0.000 title 1
- 210000000626 ureter Anatomy 0.000 abstract 2
- 102100024748 E3 ubiquitin-protein ligase UHRF2 Human genes 0.000 abstract 1
- 101710131422 E3 ubiquitin-protein ligase UHRF2 Proteins 0.000 abstract 1
- 206010046405 Ureteric injury Diseases 0.000 abstract 1
- GZTBUIDHFZUESL-VJGHJLQJSA-N [Cl-].COC1=C(CCC\C\1=C/C=C1/N(CCC(=O)NCCCO[C@@H]2[C@@H](O)[C@@H]3O[C@H]4O[C@H](CO)[C@@H](O[C@H]5O[C@H](CO)[C@@H](O[C@H]6O[C@H](CO)[C@@H](O[C@H]7O[C@H](CO)[C@@H](O[C@H]8O[C@H](CO)[C@@H](O[C@H]9O[C@H](CO)[C@@H](O[C@H]2O[C@@H]3CO)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)c2ccc3ccccc3c2C1(C)C)\C=C\C1=[N+](CCC(=O)NCCCO[C@@H]2[C@@H](O)[C@@H]3O[C@H](CO)[C@H]2O[C@H]2O[C@H](CO)[C@@H](O[C@H]4O[C@H](CO)[C@@H](O[C@H]5O[C@H](CO)[C@@H](O[C@H]6O[C@H](CO)[C@@H](O[C@H]7O[C@H](CO)[C@@H](O[C@H]8O[C@H](CO)[C@@H](O3)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]2O)c2ccc3ccccc3c2C1(C)C Chemical compound [Cl-].COC1=C(CCC\C\1=C/C=C1/N(CCC(=O)NCCCO[C@@H]2[C@@H](O)[C@@H]3O[C@H]4O[C@H](CO)[C@@H](O[C@H]5O[C@H](CO)[C@@H](O[C@H]6O[C@H](CO)[C@@H](O[C@H]7O[C@H](CO)[C@@H](O[C@H]8O[C@H](CO)[C@@H](O[C@H]9O[C@H](CO)[C@@H](O[C@H]2O[C@@H]3CO)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)c2ccc3ccccc3c2C1(C)C)\C=C\C1=[N+](CCC(=O)NCCCO[C@@H]2[C@@H](O)[C@@H]3O[C@H](CO)[C@H]2O[C@H]2O[C@H](CO)[C@@H](O[C@H]4O[C@H](CO)[C@@H](O[C@H]5O[C@H](CO)[C@@H](O[C@H]6O[C@H](CO)[C@@H](O[C@H]7O[C@H](CO)[C@@H](O[C@H]8O[C@H](CO)[C@@H](O3)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]2O)c2ccc3ccccc3c2C1(C)C GZTBUIDHFZUESL-VJGHJLQJSA-N 0.000 abstract 1
- 229940072418 pudexacianinium chloride Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000012800 visualization Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163226534P | 2021-07-28 | 2021-07-28 | |
| PCT/IB2022/056957 WO2023007404A1 (en) | 2021-07-28 | 2022-07-27 | Pudexacianinium for nirf imaging |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001242A true MX2024001242A (es) | 2024-02-13 |
Family
ID=82898903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001242A MX2024001242A (es) | 2021-07-28 | 2022-07-27 | Una composicion farmaceutica para la obtencion de imagenes. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240342316A1 (https=) |
| EP (1) | EP4376896A1 (https=) |
| JP (1) | JP2024527715A (https=) |
| KR (1) | KR20240041952A (https=) |
| CN (1) | CN117715661A (https=) |
| AU (1) | AU2022321011A1 (https=) |
| CA (1) | CA3226034A1 (https=) |
| MX (1) | MX2024001242A (https=) |
| WO (1) | WO2023007404A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4605020A1 (en) * | 2022-10-21 | 2025-08-27 | Astellas Pharma, Inc. | Composition for near infrared lymphatic imaging and uses and dosages therefor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE041616T2 (hu) | 2010-01-28 | 2019-05-28 | National Univ Corporation Mie Univ | Indocianin vegyület, szintézisének eljárása, tisztítási eljárása, indocianin vegyületet alkalmazó diagnosztikai készítmény, és készülék in vivo kinetika mérésére és készülék keringés megjelenítésére a diagnosztikai készítmény alkalmazásával |
-
2022
- 2022-07-27 CN CN202280052692.7A patent/CN117715661A/zh active Pending
- 2022-07-27 KR KR1020247005443A patent/KR20240041952A/ko active Pending
- 2022-07-27 MX MX2024001242A patent/MX2024001242A/es unknown
- 2022-07-27 US US18/291,487 patent/US20240342316A1/en active Pending
- 2022-07-27 AU AU2022321011A patent/AU2022321011A1/en active Pending
- 2022-07-27 WO PCT/IB2022/056957 patent/WO2023007404A1/en not_active Ceased
- 2022-07-27 EP EP22754545.6A patent/EP4376896A1/en active Pending
- 2022-07-27 CA CA3226034A patent/CA3226034A1/en active Pending
- 2022-07-27 JP JP2023580416A patent/JP2024527715A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3226034A1 (en) | 2023-02-02 |
| US20240342316A1 (en) | 2024-10-17 |
| KR20240041952A (ko) | 2024-04-01 |
| CN117715661A (zh) | 2024-03-15 |
| WO2023007404A1 (en) | 2023-02-02 |
| AU2022321011A1 (en) | 2024-01-25 |
| EP4376896A1 (en) | 2024-06-05 |
| JP2024527715A (ja) | 2024-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2705016T3 (es) | Derivado de rapamicina para el tratamiento de cáncer de pulmón | |
| JP5911929B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| Shaikh et al. | Dexmedetomidine as an adjuvant to hyperbaric spinal bupivacaine for infra-umbilical procedures: A dose related study | |
| JP2021516262A (ja) | リツキシマブ及び／若しくはベンダムスチンと組み合わされたＢｃｌ−２阻害剤又はＣＨＯＰと組み合わされたＢｃｌ−２阻害剤の相乗的な抗腫瘍効果 | |
| UA75450C2 (en) | Use of polysaccharide conjugates for inhibiting metastasis or preventing recurrence of malignant tumor | |
| MX2024001242A (es) | Una composicion farmaceutica para la obtencion de imagenes. | |
| JP2019501948A (ja) | 化学療法で誘導される末梢神経障害の治療に使用するためのｉｌ−８阻害剤 | |
| RU2375058C2 (ru) | Комбинации, включающие эпотилоны, и их фармацевтическое применение | |
| US10617667B2 (en) | Method for treating brain tumors | |
| JP2020502182A5 (https=) | ||
| US20120295871A1 (en) | Heparin-based compositions and methods for the inhibition of metastasis | |
| Hollebecque et al. | Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients | |
| Malik et al. | Combined Psoas Compartment and Sciatic Nerve Block for Lower Limb Surgery: An Alternative Anesthetic Option in High‑risk Geriatric Patients | |
| ES3015427T3 (en) | Use of non-peptide nk1 antagonists in a predetermined dose for the treatment of cancer | |
| JP2019517474A5 (https=) | ||
| ECSP12012350A (es) | Formulación de liberación sostenida | |
| Ikegaki et al. | Delirium Prolonged for Three Days after Addition of One Dose of 5 mg Methadone to Ongoing Opioid | |
| Yang et al. | Pleural effusion and atelectasis during continuous interscalene brachial plexus block-A case report | |
| Lee et al. | Total intravenous anesthesia using remimazolam for patients with heart failure with reduced ejection fraction: a case series | |
| Vandepitte et al. | “Don't Throw the Baby Out With the Bath Water:” A Reply to Dr. Onwochei et al | |
| RU2549474C1 (ru) | Способ премедикации перед оперативными гинекологическими вмешательствами, выполняемыми в условиях общей анестезии | |
| Tsygankov et al. | Comparison of hemodynamic parameters in patients during transcuretral resection of the urinary bubble during spinal anesthesia using levobupivakaina and popivacaine | |
| AU2014227478A1 (en) | Filanesib combined with pomalidomide displays enhanced anti-tumor activity | |
| Aytuluk et al. | LETTER TO THE EDITOR DOI: 10.5055/jom. 2019.0490 | |
| WO2006062072A1 (ja) | 転移癌治療剤および癌転移抑制剤 |